<DOC>
	<DOCNO>NCT01115855</DOCNO>
	<brief_summary>A study compare efficacy safety eplerenone Japanese chronic heart failure patient placebo .</brief_summary>
	<brief_title>Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure</brief_title>
	<detailed_description>The aim study show consistency EMPHASIS-HF trial ( NCT00232180 ) , define HR primary endpoint 1 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Japanese chronic systolic heart failure patient LVEF = &lt; 30 % echocardiography NYHA II Patients receive standard therapy ( Angiotensin convert enzyme inhibitor , angiotensin receptor blocker , betablocker diuretic ) Patients myocardial infarction , stroke , cardiac surgery percutaneous coronary intervention within 30 day prior randomization . Patients serum potassium &gt; 5.0 mmol/L eGFR &lt; 30 ml/min/1.73 m2 .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>eplerenone</keyword>
	<keyword>Japanese</keyword>
</DOC>